OncRef

Clinical Trial: NCT02642042

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-09-04

Study Overview

Brief Summary

This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib with docetaxel may work better in treating non-small cell lung cancer.

Official Title

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies

Conditions

KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Intervention / Treatment

  • Drug: Docetaxel
  • Other: Laboratory Biomarker Analysis
  • Drug: Trametinib

Other Study ID Numbers

  • NCI-2015-02250
  • NCI-2015-02250
  • S1507
  • S1507
  • S1507
  • U10CA180888

Start Date (Actual)

2016-07-18

Primary Completion Date (Actual)

2019-05-15

Study Completion Date (Estimated)

2027-03-03

Enrollment (Actual)

60

Study Type

Interventional

Phase

Phase 2